Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93397&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Humana Inc. (HUM) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Delaware on behalf of all persons and entities who purchased securities of Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) between July 27, 2022 and January 24, 2024, inclusive (the “Class Period”).

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Humana, Inc. (HUM)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) common stock between July 27, 2022 and January 24, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On June 13, 2023, one of Humana's primary competitors, UnitedHealth Gr.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humana Inc. (HUM)

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93353&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Humana Inc. Should Contact Levi & Korsinsky Before August 2, 2024 to Discuss Your Rights - HUM

LOS ANGELES--(BUSINESS WIRE)--HUM Investors Have the Opportunity to Join Humana Inc. Securities Fraud Investigation with the Schall Law Firm.

HUM Investors Have the Opportunity to Join Humana Inc. Securities Fraud Investigation with the Schall Law Firm

LOS ANGELES, Aug. 1, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE: HUM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

HUM Investors Have Opportunity to Lead Humana Inc. Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93331&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Humana Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 2, 2024 - HUM

Humana Inc. NYSE: HUM is a leading health insurer predominantly focused on Medicare Advantage plans, serving millions of individuals and families nationwide. The company's business model centers on offering a comprehensive range of health insurance products, including Medicare, Medicaid, individual, and employer-sponsored plans, along with a growing portfolio of healthcare services.

Humana Slides on Profitability Concerns Despite Q2 Earnings Beat

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93260&wire=1 or contact Joseph E. Levi, Esq.

Humana Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - HUM

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humana securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period").

IMMINENT HUM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Humana Inc. Investors to Join the Class Action Lawsuit!

Humana's (HUM) second-quarter results reflect overall premium growth and a well-performing CenterWell unit, partly offset by elevated costs. It expects individual MA membership to record growth of 225,000 in 2024.

Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93232&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Humana Inc. (HUM) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93231&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Humana Inc. (HUM) should contact Levi & Korsinsky about pending Class Action - HUM

LOS ANGELES, July 31, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) common stock between July 27, 2022, and January 24, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humana Inc. (HUM)

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Humana Inc. ("Humana" or the "Company") (NYSE: HUM) of a class action securities lawsuit.

Humana Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before August 2, 2024 to Discuss Your Rights – HUM

Humana, Inc. (NYSE:HUM ) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET Company Participants Lisa Stoner - Vice President, Investor Relations James Rechtin - President and Chief Executive Officer Susan Diamond - Chief Financial Officer Conference Call Participants Ann Hynes - Mizuho Sarah James - Cantor Fitzgerald Andrew Mok - Barclays Justin Lake - Wolfe Research David Windley - Jefferies A.J. Rice - UBS Kevin Fischbeck - Bank of America Josh Raskin - Nephron Research Ben Hendrix - RBC Capital Markets Stephen Baxter - Wells Fargo Scott Fidel - Stephens Lance Wilkes - Bernstein Michael Ha - Baird Jessica Tassan - Piper Sandler John Ransom - Raymond James George Hill - Deutsche Bank Erin Wright - Morgan Stanley Ryan Langston - TD Cowen Operator Good day, and thank you for standing by.

Humana, Inc. (HUM) Q2 2024 Earnings Call Transcript

The headline numbers for Humana (HUM) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Humana (HUM) Q2 Earnings: A Look at Key Metrics

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93190&wire=1 or contact Joseph E. Levi, Esq.

Humana Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 2, 2024 to Discuss Your Rights - HUM

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Humana To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Humana stock or options between July 27, 2022 and January 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/HUM.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humana

Humana (HUM) came out with quarterly earnings of $6.96 per share, beating the Zacks Consensus Estimate of $5.89 per share. This compares to earnings of $8.94 per share a year ago.

Humana (HUM) Surpasses Q2 Earnings and Revenue Estimates

Humana Inc.'s stock HUM was down 3.5% in premarket trading on Wednesday after the health insurance giant said its profit fell, although its adjusted earnings beat analyst expectations. Humana said its second-quarter net income dropped to $918 million, or $5.62 a share, from $1.26 billion, or $7.66 a share in the year-ago quarter.

Humana's revenue and adjusted profit beat analyst estimates, but stock dips

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended June 30, 2024 (2Q24) versus the quarter ended June 30, 2023 (2Q23) and for the six months ended June 30, 2024 (YTD 2024) versus the six months ended June 30, 2023 (YTD 2023) as noted in the tables below. Consolidated income before income taxes and equity in net earnings (pretax results) In millions 2Q24 (a) 2Q23 (a) YTD 2024 (a) YTD 2023.

Humana Reports Second Quarter 2024 Financial Results; Affirms Full Year Adjusted 2024 Financial Guidance

LOS ANGELES--(BUSINESS WIRE)--HUM Investors Have Opportunity to Lead Humana Inc. Securities Fraud Lawsuit with the Schall Law Firm.

HUM Investors Have Opportunity to Lead Humana Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / July 30, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93061&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Humana Inc.(HUM) should contact Levi & Korsinsky about pending Class Action - HUM

NEW YORK, NY / ACCESSWIRE / July 30, 2024 / If you suffered a loss on your Humana Inc. (NYSE:HUM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humana-lawsuit-submission-form?prid=93046&wire=1 or contact Joseph E. Levi, Esq.

News for Humana Stock (HUM)